Xellia Pharmaceuticals Announces the Launch of First US Market Product Vancomycin Hydrochloride for Injection, USP
Now offering Vancomycin HCl, USP 10 g and 1 g lyophilized powder in the United States market.
BUFFALO GROVE, Ill. & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced today it has launched Vancomycin Hydrochloride for Injection, USP within the United States market.
“Today marks an important milestone for our US market strategy and represents a significant step forward in the company's evolution as we bring the first product to the US market under the Xellia brand,” said Carl-Aake Carlsson, Xellia’s CEO.
Craig Boyd, President of Xellia North America, said: “As a leading global supplier of Vancomycin API, we are excited to now offer Vancomycin 1 g and 10 g in the US from our vertically integrated supply chain and significant injectable manufacturing footprint. This is the first of many key launches that will bring Xellia’s strong portfolio of established and innovative products to patients in need of critical anti-infective treatments.”
Full prescribing information for Vancomycin Hydrochloride for Injection, USP can be found at www.xellia.com/us
The product has an estimated market size of $338M for the twelve months ending August 2018 according to IQVIA*.
*IQVIA National Sales Perspectives: Retail and Non-Retail Forms TLC F,G and K: MAT August 2018
About Xellia Pharmaceuticals
Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.
With over 100 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable drug products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.
Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia and North America and is investing significantly to expand its sales and manufacturing capabilities within the United States. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,500 people.
Further information about Xellia can be found at: www.xellia.com.
Craig Boyd / Katarina Simonovic
Tel: +1 312 951 3809
Instinctif Partners (International media relations)
Eileen Paul / Rozi Morris / Melanie Toyne-Sewell
Tel: +44 (0) 20 7457 2020
Source: Xellia Pharmaceuticals